Leerink Affirms ACADIA Pharma (ACAD) at 'Outperform'; Pimavanserin Briefing Docs More Crticial than Expected
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM EDTNeedham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
Acadia Pharma (ACAD) Halted Ahead of FDA PDAC Review of NUPLAZID
March 29, 2016 7:05 AM EDTACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that NASDAQ has halted trading of the companys common stock.
The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to review NUPLAZID (pimavanserin) for the treatment of patients with... More
Acadia Pharma's (ACAD) Buy Rating Reiterated at H.C. Wainwright Ahead of Nuplazid's Adcom Meeting
March 28, 2016 7:52 AM EDTH.C. Wainwright reiterated a Buy rating on Acadia Pharmaceuticals (NASDAQ: ACAD) with a price target of $50. Comments follow the release of FDA briefing documents for tomorrow's Nuplazid FDA adcom panel. Analyst Andrew S. Fein said he remains confident that clinical benefits outweigh risks.
"As anticipated, the discussion will center on clinical meaningfulness of the 3-point improvement on SAPS-PD and risk/reward in light of safety signals, including potential... More
Wall Street ends flat after choppy session
March 28, 2016 7:23 AM EDTBy Noel Randewich
(Reuters) - Wall Street was mixed on Monday as weaker-than-expected U.S. economic data reduced concerns about potential interest rate hikes and a dip in oil prices pushed down energy shares.
U.S. consumer spending barely rose in February and inflation retreated, suggesting the Federal Reserve could remain cautious about raising interest rates this year even as the labor market rapidly tightens.
Trading was choppy and volume was low, with markets closed in Europe.
The S&P has mostly recovered from a 10-percent loss at the start of 2016 but many investors remain... More
Acadia Pharma (ACAD) Shares Active Ahead of NUPLAZID FDA Panel
March 28, 2016 7:03 AM EDTAcadia Pharma (NASDAQ: ACAD) shares advanced pre-market after the FDA posted briefing documents ahead of its NUPLAZID panel on March 29. The documents are embedded below:
... More